RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • August 21st, 2015 • Ziopharm Oncology Inc • Services-specialty outpatient facilities, nec • Texas
This RESEARCH AND DEVELOPMENT AGREEMENT (the “AGREEMENT”) is entered into as of August 17, 2015 (the “EFFECTIVE DATE”) by and among THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a member institution of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), ZIOPHARM ONCOLOGY, INC., a Delaware corporation (“ZIOPHARM”), and INTREXON CORPORATION, a Virginia corporation (“INTREXON”). ZIOPHARM and INTREXON are referenced herein collectively as the “LICENSEE”.
